Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
#TradFi交易分享挑战 According to publicly available information, as of May 22, 2026, Moderna (stock ticker: MRNA)’s market performance and analysis are as follows:
1. Stock Price Performance
Recent stock price fluctuations have been significant, with a brief rise on May 12 due to hantavirus news followed by a decline, closing at approximately $52.88, with an increase of about 11.8% over the past five trading days.
Since January 1, 2026, the stock price has risen from [formula] 51.62, an increase of approximately 73.1%, but has not yet recovered to the peak levels of 2021.
2. Fundamental Drivers
Cancer vaccine progress: The mRNA-4157 (Intismeran Autogene) cancer vaccine developed in partnership with Merck has published five-year follow-up data in the melanoma adjuvant treatment field, showing that combined treatment with Keytruda can reduce the risk of recurrence or death by 49%, which boosts market confidence in its oncology pipeline potential.
Other pipeline advancements: Influenza vaccine mRNA-1010, RSV vaccine mRNA-1385, and others are in Phase 3 trials, with potential approval in 2026, supporting future revenue growth.
Financial adjustments: The company has improved its financial position through cost reductions and financing (such as a $1.5 billion loan agreement with Ares Management), with an expected revenue growth of about 10% in 2026, aiming to achieve operational cash flow breakeven.
3. Market Sentiment and Risks
Market attention to its oncology vaccine pipeline is high, but Phase 3 clinical data has not yet been fully released, creating uncertainty. If subsequent data fail to reproduce early results, it could impact the stock price.
Regulatory environment changes (such as increased vaccine approval thresholds in the U.S.) and political factors (some states restricting mRNA vaccines) remain risks, potentially delaying product launches or affecting market promotion.
Overall, Moderna is currently in a critical transition period, with its oncology vaccine pipeline being the core driver of future growth, but key clinical data validation is needed, and stock price volatility may continue. Investors should monitor the release of clinical data and regulatory developments after 2026. $MRNA
1. Stock Price Performance
Recent stock price fluctuations have been significant, with a brief rise on May 12 due to hantavirus news followed by a decline, closing at approximately $52.88, with an increase of about 11.8% over the past five trading days.
Since January 1, 2026, the stock price has risen from [formula] 51.62, an increase of approximately 73.1%, but has not yet recovered to the peak levels of 2021.
2. Fundamental Drivers
Cancer vaccine progress: The mRNA-4157 (Intismeran Autogene) cancer vaccine developed in partnership with Merck has published five-year follow-up data in the melanoma adjuvant treatment field, showing that combined treatment with Keytruda can reduce the risk of recurrence or death by 49%, boosting market confidence in its oncology pipeline potential.
Other pipeline advancements: Influenza vaccine mRNA-1010, RSV vaccine mRNA-1385, and others are in Phase 3 trials, with potential approval in 2026, supporting future revenue growth.
Financial adjustments: The company has improved its financial position through cost reductions and financing (such as a $1.5 billion loan agreement with Ares Management), with an expected revenue growth of about 10% in 2026, aiming to achieve operational cash flow breakeven.
3. Market Sentiment and Risks
Market attention to its oncology vaccine pipeline is high, but Phase 3 clinical data has not yet been fully released, creating uncertainty. If subsequent data fail to reproduce early results, it could impact the stock price.
Regulatory environment changes (such as increased vaccine approval thresholds in the U.S.) and political factors (some states restricting mRNA vaccines) remain risks, potentially delaying product launches or affecting market promotion.
Overall, Moderna is currently in a critical transition period, with its oncology vaccine pipeline being the core driver of future growth, but key clinical data validation is needed, and stock price volatility may continue. Investors should monitor upcoming clinical data releases and regulatory developments in 2026. $MRNA